secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2022-12-22T23:59:59+00:00
Accession:  0001193125-22-311070
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Pharma to acquire U.S. rights of FYCOMPA from Eisai for $160M upfront
------------------------------------------------------------------------------

- $160M upfront at closing; potential $25M milestone if patent exclusivity extended to June 2026.
- FYCOMPA U.S. net revenues approx. $136M for Eisai fiscal year ending March 2023.
- Deal expected to be EBITDA and EPS accretive in 2023; all-cash, no financing contingencies.
- Includes exclusive option to evaluate and negotiate acquisition of a rare epilepsy pipeline asset.
- Expected close Q1 2023, subject to customary closing conditions and U.S. regulatory clearances.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312522311070/0001193125-22-311070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312522311070/d432372d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-311070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer